Talks to replace Novo Nordisk CEO lasted several weeks, board chair says
COPENHAGEN, May 16 (Reuters) - Discussions between Novo Nordisk (NOVOb.CO), opens new tab and the Novo Nordisk Foundation that controls the company regarding a CEO change have been ongoing for the past few weeks, the company's board Chair Helge Lund told Reuters on Friday.
Meanwhile, outgoing Chief Executive Lars Fruergaard Jorgensen told Danish broadcaster TV2 that he was surprised by the decision, and that he had only been informed "very recently".
"I did not see this coming," Fruergaard Jorgensen told TV2.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
9 hours ago
- Reuters
T-Mobile US boss set to leave post early, Handelsblatt newspaper reports
FRANKFURT, June 9 (Reuters) - The head of T-Mobile U.S. (TMUS.O), opens new tab, the fast-growing and profitable subsidiary of Germany's Deutsche Telekom ( opens new tab, is due to step aside before the end of his current contract, German newspaper Handelsblatt reported on Monday. Deutsche Telekom did not immediately respond to a request for comment on the report. Handelsblatt reported Mike Sievert, who has headed the mobile operator since 2020, wanted to take a break and that Chief Operating Officer Srini Gopalan, until recently head of Deutsche Telekom's Germany business, was a leading candidate to succeed him. The chief executive would step down this year or next, the newspaper added. Previously facing troubles, T-Mobile has become a revenue and profit driver in recent years. Thanks to strong figures from the U.S. mobile operator, Deutsche Telekom has raised its earnings targets several times. T-Mobile U.S. customer growth fell short of expectations at the beginning of the year due to an intensified price war. The subsidiary nonetheless aims to win 5.5 to 6 million new users by 2025. Sievert, who joined T-Mobile as marketing head in 2012, had been due to remain in post until 2028.
Reuters
11 hours ago
- Reuters
Activist hedge fund Parvus builds stake in Novo Nordisk, FT reports
June 9 (Reuters) - Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk ( opens new tab, after the company lost its first mover advantage in the lucrative weight-loss drug market, the Financial Times reported on Monday, citing people with knowledge of the details. The London-based fund, which has targeted budget airline Ryanair (RYA.I), opens new tab and Italian bank UniCredit ( opens new tab, wants to influence the appointment of Novo Nordisk's new CEO, the report said. Novo told Reuters in an email that it does not "have anything to add." Parvus did not immediately respond to a request for comment. In May, the company announced its CEO Lars Fruergaard Jorgensen would step down after shares plunged from a record-high in June last year as competition, particularly from U.S. rival Eli Lilly (LLY.N), opens new tab, makes inroads into Novo's market share, while its pipeline of new drugs has failed to impress investors. Novo also expects its Wegovy weight-loss drug sales in the United States to start recovering once a ban on compound copycats is enforced this month, Jorgensen said last month after the company cut its 2025 forecasts.
Reuters
12 hours ago
- Reuters
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
June 9 (Reuters) - Shares of weight-loss drug developer Metsera (MTSR.O), opens new tab gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a monthly dosing regime. The drug developer, which went public in January, is one of the many that are eyeing the lucrative market of weight-loss drugs that have been dominated by GLP-1 drugs from Novo Nordisk ( opens new tab and Eli Lilly (LLY.N), opens new tab. The drug, MET-233i, helped patients lose 8.4% of their weight, when adjusted for placebo, at 36 weeks. The drug belongs to a class of medicines which mimic the pancreatic hormone amylin that is co-secreted with insulin. It is being developed as a standalone treatment, and in combination with the company's other GLP-1 drug MET-097i. The two hormones combined suppress hunger, help control patients' blood glucose. Metsera's shares, which touched $35.19 in early trading, were up 5% at midday. The first wave of obesity drugs was based mainly on the gut hormone GLP-1, but drugmakers are looking for medicines that target other hormones or help preserve muscle while losing fat for their next generation of drugs. Data from Novo Nordisk's experimental drug CagriSema, which was touted to be the successor of its blockbuster obesity drug Wegovy, has so far fallen below investor expectations. Data from Metsera's 80-patient study showed that its drug has a half life of about 19 days, supporting once-a-month dosing. This compares to the five to seven days for Lilly's Zepbound and Novo's Wegovy that are taken weekly, said Evercore ISI analyst Umer Raffat. The so-called half life of a drug refers to the time it takes for the initial dose of the medicine to decrease by half in a patient's body. It helps determine how frequently a drug should be taken to achieve benefits. Drugmaker AstraZeneca (AZN.L), opens new tab is also testing an amylin-based obesity drug in early trials.
